Swissmedic authorizes moderna's omicron-targeting bivalent booster candidate, mrna-1273.214

Switzerland becomes among the first countries in the world to approve the use of a next-generation bivalent covid-19 booster vaccine study results show mrna-1273.214 has demonstrated significantly higher antibody titers against omicron ba.1 and ba.4/5 subvariants when compared with mrna-1273 moderna is working with swissmedic and the government of switzerland to make mrna-1273.214 available in early september cambridge, ma / accesswire / august 29, 2022 / moderna, inc. (nasdaq:mrna), a biotechnology company pioneering messenger rna (mrna) therapeutics and vaccines, today announced that swissmedic has granted temporary authorization for the use of moderna's omicron-targeting bivalent booster vaccine, spikevax bivalent original/omicron (mrna-1273.214) for active immunization to prevent sars-cov-2 virus-induced coronavirus-2019 disease for individuals aged 18 years and older. spikevax bivalent original/omicron is a next-generation bivalent vaccine that contains 25 Μg of mrna-1273 (spikevax) and 25 Μg of a vaccine candidate targeting the omicron variant of concern (ba.1).
MRNA Ratings Summary
MRNA Quant Ranking